Pfizer Inc. (PFE) Earnings Call Transcript & Summary
May 5, 2026
What were the key takeaways from Pfizer Inc.'s May 5, 2026 earnings call?
In the first quarter of 2026, Pfizer Inc. (PFE) reported revenues of $14.5 billion and adjusted diluted earnings per share (EPS) of $0.75, both exceeding expectations. The company reaffirmed its full-year guidance of total revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00. Management highlighted strong growth in launched and acquired products, which saw a 22% operational increase, and indicated a positive outlook for long-term revenue growth driven by strategic investments and pipeline advancements.
What topics did Pfizer Inc. cover?
- Strong Revenue Performance: Pfizer's Q1 revenues reached $14.5 billion, reflecting a 2% operational increase. Management noted, "we exceeded expectations for both total revenues and adjusted diluted earnings per share."
- Guidance Reaffirmation: The company maintained its full-year guidance, expecting total revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. This reflects confidence in ongoing product performance and cost management.
- Growth in Launched and Acquired Products: Launched and acquired products generated $3.1 billion in Q1, achieving a 22% operational growth. This performance underscores the success of Pfizer's portfolio transition strategy.
- Oncology Product Performance: Oncology products, particularly from the Seagen acquisition, demonstrated a 20% year-over-year operational revenue growth. Management stated, "the 20% year-over-year operational revenue growth in the quarter of our Seagen products shows...good progress in deepening our presence within the oncology community."
- Legal Developments Impacting Growth Profile: Recent legal settlements regarding VYNDAMAX and COMIRNATY contracts are expected to enhance Pfizer's growth profile post-2028. Bourla noted, "this gives us greater confidence that starting in 2029 we will enter a 5-year period of high single-digit revenue CAGR."
What were Pfizer Inc.'s May 5, 2026 results?
- Revenue: $14.5 billion (+2% operationally)
- Adjusted Diluted EPS: $0.75 (exceeding expectations)
- Launched and Acquired Products Revenue: $3.1 billion (+22% operationally)
- Adjusted Gross Margin: 76%
- Operating Cash Flow: $2.6 billion
Pfizer's strong Q1 performance and reaffirmed guidance indicate a solid foundation for growth, particularly through its oncology and launched products. The company's strategic focus on R&D and cost management, combined with positive legal developments, positions it well for future revenue growth. Investors should monitor the execution of pipeline advancements and any shifts in COVID-19 vaccine demand as potential catalysts or risks.
Earnings Call Speaker Segments
Hello everyone, and thanks for joining Pfizer's earnings call this morning. My name is Francesca DeMartino, and I serve as Chief Investor Relations Officer; the Pfizer team appreciates your participation; an audio webcast of this call can be accessed at pfizer.com. Our first quarter 2026 results were issued earlier today through a press release, which you can find on our website at pfizer.com. With me today are Dr. Albert Bourla, our Chairman and CEO, and Dave Denton, our CFO. Albert and Dave will deliver some prepared remarks, and after that we'll take questions from the call. Our leadership team members will be on hand for the Q&A session. Before we begin, please note that forward-looking statements will be made and certain non-GAAP financial measures will be discussed. I'd ask you to review the disclaimers in our slide presentation, the press release from this morning, and the disclosures in our SEC filings, all of which can be found on the IR website at pfizer.com. Any forward-looking statements made on this call carry substantial risks and uncertainties, are valid only as of the call's original date, and no obligation is undertaken by us to update or revise any of them. With that said, I'll hand things over to Albert.
Thank you, Francesca. Everyone, good morning, and I appreciate your joining this call. It's a lovely day here in New York; for us, the year has opened on a strong note. Our business is performing well across the board, and our strategy is advancing. Execution ranks among our greatest strengths, and even as we invest to make Pfizer stronger for the growth and impact of tomorrow, we continue delivering on the financial commitments we've made. In Q1, we exceeded expectations for total revenues and for adjusted diluted earnings per share. Thus far in 2026, we've progressed on the critical R&D milestones we established, delivering three positive phase III readouts along with encouraging mixed readouts spanning approved and investigational medicines. About 20 pivotal study starts are on the docket for this year, and that ambitious schedule remains on track. We also saw two significant legal developments, which enhance our growth profile past 2028 and, of course, our cash flow outlook. Under the settlement agreements we reached recently, resolving patent infringement related to VYNDAMAX, there's potential to substantially reshape the company's growth after 2028. That strengthens our confidence that starting in 2029, a five-year period of high single-digit revenue CAGR gets underway. Beyond that, the recent Belgium court ruling concerning COMIRNATY contracts with EU member countries strikes us as favorable for future EPS and cash flow. With a clearer picture of our cash flow, our longer-term capital allocation priorities receive a boost — including, of course, protecting and sustaining the dividend. Shifting to the rest of the year, our focus is firmly on the opportunities that matter most for creating value for patients and for our shareholders. We set out our strategic priorities for 2026 earlier, and I'll walk you through how each of the four is progressing. Our launched and acquired products began the year exceptionally well, with 22% growth. Approximately 8% of the invested capital from recent years is tied up in three of our business development transactions, and each one is performing quite well. Oncology stands as our most advanced and concentrated research and commercial area, and our Seagen acquisition is a major reason why. Since that company joined Pfizer, we've restructured our oncology organization — uniting our team, expanding our commercial portfolio, and advancing a leading ADC platform. This quarter, operational revenue for our Seagen products climbed 20% year over year, showing solid progress in strengthening our position within the oncology community. We continue building physician engagement and driving greater recognition of the clinical value our medicines deliver. Likewise, we're executing with discipline to maximize our Metsera acquisition. This underpins the strategy aimed at establishing Pfizer as a leader in the next generation of obesity therapies — a field where 436,000 new cases arise each year in the United States. This year, we intend to advance 10 phase III studies. Our goal is an initial approval in 2028, stemming from a portfolio featuring ultra-long-acting peptides. Should those pan out, they might be developed and approved with efficacy and tolerability that compete well, along with a differentiated maintenance schedule of once-monthly dosing. Our achievements with NURTEC since acquiring Biohaven illustrate how capable our top-tier field force and commercial team are. During Q1, NURTEC posted 41% operational growth, driven by robust demand in both acute and preventive migraine therapies, and within the oral CGRP category of migraine medicines we continue to perceive considerable room for expansion. That said, 2026 stands as a crucial year for R&D, and I'm pleased by how much we've already progressed this quarter. Our pipeline in development is extensive, yet we allocate resources in a rigorous, disciplined manner toward the highest-potential opportunities. During this year, we're targeting approximately 20 pivotal trials getting underway, eight significant data readouts, and four regulatory decisions. These essential R&D milestones illustrate how investment is being concentrated in priority areas such as oncology, metabolic disease, and vaccines — domains in which we possess existing commercial infrastructure, scientific know-how, and ample opportunity for competitive differentiation. Of the significant data readouts and regulatory decisions expected during 2026, about half ought to come from oncology, where numerous programs are moving forward in breast, genitourinary, thoracic, gastrointestinal, and blood cancers. This quarter, we presented important EV-304 results for PADCEV at ASCO GU. Those findings show that combining PADCEV with pembrolizumab reduces the likelihood of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer patients. Together with the recently reported compelling EV-303 trial data, this highlights how the regimen might become the new standard of care for muscle-invasive bladder cancer patients, no matter their cisplatin eligibility. Globally, over 600,000 individuals receive a bladder cancer diagnosis annually, with an estimated 85,000 of those in the U.S. Among all bladder cancer cases, approximately 30% are MIBC. Last week's positive top-line results from the phase III MagnetisMM-5 trial of ELREXFIO represent a meaningful advance toward our goal of treating more patients earlier in their disease journey. In that study, ELREXFIO delivered a significant improvement in progression-free survival for double class-exposed relapsed or refractory multiple myeloma patients who had undergone at least one prior line of therapy. That points to a considerable opportunity for addressing patient need. Multiple myeloma — an aggressive blood cancer with no cure at present — is the second most common blood cancer around the world, with over 36,000 new U.S. cases each year and more than 187,000 new cases globally. Additionally, during the quarter we observed randomized phase II data for atirmociclib, our potential first-in-class CDK4 inhibitor, among HR+/HER2- breast cancer patients previously treated with CDK4/6 inhibitor-based therapy. Those data suggest atirmociclib may set itself apart from the CDK4/6 inhibitor class via improved efficacy and tolerability, which bolsters our confidence in the molecule. Looking ahead, our focus remains on accelerating development of this investigational medicine in first-line and early breast cancer, where patients could gain even greater benefit. We view this as a major opportunity to advance a next-generation backbone therapy, carrying on Pfizer's long-standing commitment to individuals battling breast cancer. Turning to vaccines, we have been in discussions with regulators regarding how to widen coverage through our next-generation pneumococcal conjugate vaccine, allowing us to build on our leadership position in this fiercely competitive space. As of yesterday, our phase III program began for the 25-valent pediatric vaccine candidate, which offers greater valency plus next-generation serotype 3 technology. I'm also pleased to share an update on our strategy for the adult market. We have decided to proceed directly with our fifth-generation adult vaccine candidate. Today, I'm thrilled to disclose for the first time that it spans 35 serotypes. We believe this gives us the strongest position to maintain our current market leadership in the adult segment over the long term, and we expect to launch clinical development within this year. In I&I, during March we announced a positive readout from a phase II trial of tilrekimig, our investigational trispecific antibody targeting atopic dermatitis. We intend to advance a broad clinical development program for this investigational medicine, which originated from in-house discovery at Pfizer and is currently being assessed in atopic dermatitis, asthma, and COPD. With 436,000 new cases each year in the United States, this work matters enormously.
Our dedication is unchanged, and we keep concentrating on the thing that counts the most: getting the greatest long-term worth out of our pipeline for patients overall. Our investments are made with strategic discipline and attention, aimed at constructing the basis that supports our objective of a five-year revenue CAGR in the high single digits; it's essential that our R&D organization possesses the means to push forward our strong pipeline, covering both programs found internally and possibilities we've brought in via strategic actions, for example our purchase of Metsera plus our in-licensing deals with 3SBio and YaoPharma. When it comes to converting scientific advances into impact in the real world, our commercial teams lead the way. We're expanding investments so they have the capabilities, technology, and support needed, which helps our medicines get to the right patients at the right moment, allowing us to provide lasting value. Our commitment to shareholders also runs deep; we plan to keep our dividend and, as time goes on, increase it while we keep delivering and building value over the long term. A central strategic priority is weaving artificial intelligence throughout our entire company, and we're generating ongoing momentum in R&D, commercial, manufacturing, and core enterprise functions; by combining frontier AI tools customized to function and role with thorough training that's continually refreshed, we enable our colleagues to speed up innovation. Among the fields where we perceive the greatest potential is the discovery, development, and delivery of new medicines and vaccines. Using AI's power to shorten timelines and sharpen decision-making sits at the heart of our innovation strategies. We're integrating AI into every functional line of R&D. Pfizer holds an enormous repository of translational and clinical data on small and large molecules, and AI is opening the chance to reveal insights that might significantly affect the way we discover and develop medicines and vaccines. With that, I'll now hand things over to Dave, who will discuss the company's financial performance.
Okay, thanks, Albert. Good morning, everyone. I want to start by pointing out that the solid performance we posted in the first quarter shows how we keep executing with discipline against our strategic priorities, and just as important, it shows the progress we keep making in repositioning this company for sustainable growth. The investments we're making now are targeted ones, meant to fuel revenue growth later in this decade and beyond. As we look forward, Pfizer is moving into a new phase. Between the products we've launched and acquired and a pipeline that's getting stronger, we're positioning this company so that it can deliver growth toward the end of the decade. While we continue concentrating on navigating the LOE challenges right in front of us, we are also busy preparing the foundation for value that lasts over the long haul. Against that backdrop, I'll take you through what we delivered in Q1, cover how we're thinking about deploying capital, and wrap up by revisiting our 2026 outlook, which we're confirming again as of today. Turning to the quarter: for the first three months of 2026, we recorded $14.5 billion in revenue. That figure topped what we had projected and represents a 2% operational gain. Excluding the revenue tied to our COVID offerings, the core business grew about 7% on an operational basis, reflecting healthy demand for major brands and ongoing strength in how we execute commercially. On earnings, diluted EPS for the first quarter came in at $0.47 as reported, while adjusted diluted EPS reached $0.75, both ahead of what we had anticipated. Together with our robust top line, that beat also highlights the sustained work we're doing to control costs and boost productivity throughout the company. The outcome for this quarter shows how well our sharpened commercial approach is working; contributions were steady across our portfolio, led mainly by PADCEV, ELIQUIS, NURTEC, LORBRENA, and the VYNDAQEL family, with each one demonstrating disciplined execution within our priority therapeutic areas. During Q1, the products we've launched along with those we acquired brought in $3.1 billion, and operationally our revenues rose roughly 22%; what these figures show is the initial effect of both our portfolio transition and the ways we're investing, and we'll keep putting money behind these product groups so they can keep growing, which we believe will let the company partly counterbalance the LOE headwinds coming in the next few years. For Q1, adjusted gross margin came in at about 76%, driven mainly by the mix of products sold this quarter plus our continued efforts to hold down costs. One thing I want to mention: accrued royalty expense ran higher this quarter, which squeezed gross margin relative to Q1 of the prior year. That being said, keeping a tight grip on costs throughout our manufacturing network is still one of our highest priorities. As a reminder, when you set COMIRNATY aside—since profits on that product are divided evenly, 50/50, with our partner BioNTech—our adjusted gross margins have typically stayed somewhere between the mid and upper seventies over the last several years. For this year, our expectation remains roughly $700 million in savings coming from phase I of the manufacturing optimization program, and about $175 million of that was achieved during this quarter. Turning to the first quarter of 2026, adjusted operating expenses totaled $5.5 billion, representing a 4% operational increase relative to the same period a year earlier. Breaking that down, adjusted SI&A costs fell 5% on an operational basis, largely because we spent less on marketing and promotions across a number of products — a result of shifting toward more targeted investments and the productivity gains we keep making — plus reduced spending in corporate enabling functions. On the adjusted R&D side, expenses climbed 11% operationally, mostly from putting more money behind selected oncology and obesity candidates. Our adjusted operating margin for the first quarter of 2026 came in strong at 38%, sitting above where it stood before the pandemic, which speaks to how well we're managing costs alongside our revenue performance. On the productivity front, we've made solid headway already, and the expectation of capturing the bulk of that $7.2 billion in net cost savings by the close of 2026 remains intact. As we move ahead, the search for additional efficiency opportunities will continue, though we'll prioritize the investments needed to power future growth. Turning to the bottom line, diluted earnings per share for Q1 was reported at $0.47, unchanged from before, and adjusted diluted EPS landed at $0.75, supported by robust non-COVID revenue and a cost-efficient operating model. That leads into capital allocation. Our strategy is designed to generate long-term shareholder value while preserving flexibility. Our approach involves funding the company's growth where the returns make sense, maintaining the dividend and increasing it as time goes on, and preserving flexibility for upcoming opportunities that could add value, including buying back stock. In the first quarter, we invested $2.5 billion in internal R&D, gave back $2.4 billion to shareholders via the quarterly dividend, and there was very little business development activity completed; the sale of our ViiV stake closed in Q2, bringing us about $1.65 billion in net proceeds after taxes and typical closing costs. When you include the ViiV proceeds, our BD capacity is roughly $7 billion. For Q1 of 2026, operating cash flow came to $2.6 billion, and leverage ended the quarter at around 2.8x. As a quick reminder, because of the loss of exclusivity pressures arriving in the coming years, our leverage should remain around where it is now, or possibly somewhat elevated, for the duration of that transition. I'd add that our last TCJA repatriation tax installment, about $2.6 billion, was paid in April. With the results we've delivered to this point and the execution we keep demonstrating, we are restating our full-year 2026 guidance as of today. Our guidance remains unchanged: overall revenue for the company should come in somewhere from $59.5 billion to $62.5 billion, and adjusted diluted EPS is projected to fall between $2.80 and $3.00 per share. That forecast assumes robust performance throughout the product portfolio, adjusted gross margins landing in the mid-70s range, careful control of costs, and continued spending on growth initiatives that carry us to the close of this decade. Keep in mind that if COVID disease levels remain consistently low, PAXLOVID usage will probably continue to face pressure over the coming months. Beyond that, our plan anticipates that most COMIRNATY revenue will arrive late in the year, matching the pattern of the vaccination season. We're still keeping an eye on how exchange rates are moving as we go through the year, as we always do. To wrap up, our priorities for the coming years are putting money into the assets that matter most and handling the LOE events ahead, which fall mainly between now and 2028. When we get to the latter part of the decade, we expect our pipeline of R&D in development, plus the ongoing momentum of products we've launched and bought, to drive growth. With the VYNDAMAX settlement behind us, we can now see a clear path to a five-year revenue CAGR in the high single digits once we're past 2028. On top of that, this development, together with the legal victory we secured in the Belgium court over the EU COMIRNATY contract, will strengthen our cash flow after 2028. We'll keep working to set Pfizer up for lasting growth over the long term and for shareholder value. With that, I'll hand the call back to Albert so we can start the Q&A.
Thanks, Dave. Nice quarter; now, operator, please assemble the queue.
Thanks. Appreciate you taking this, and I'll stick to a single one. There seems to be a lot of attention on the ADA meeting that's coming up. Could you just sort of spell out precisely what we ought to be looking for there? I realize many of us are going to see VESPER-3, but is there any additional data we should be anticipating from a Pfizer standpoint? My understanding is that you'll be holding an investor event alongside the meeting, so I'm wondering whether there are further specifics you can offer about that too. Thanks.
Chris, this one's directed at you. What portion of the data will you be revealing at the ADA?
Thanks a lot for asking that. This is clearly a hugely significant program, and we're pleased about how things are going. From the time Metsera closed, as you're aware, our execution has been outstanding — not just in clinical development, but on the commercial side too, plus CMC, pharmaceutical sciences, and the devices. We'll be sharing detailed phase III results from VESPER-3. The top-line figures we showed previously, I believe, during the full Q 25 earnings. Results from VESPER-1, the open-label extension, are going to be shared, and so will data from VESPER-2, which covers weekly berobenatide — that's the new name for our GLP-1 — with or without titration in participants who have type 2 diabetes. At ADA, we won't be sharing data on amylin mono just yet. We're expecting 24 weeks of monotherapy and 28 weeks of combination with the amylin and GLP-1. That's going to be shared in the second half of this year.
Thanks, Chris. Let's take the next one.
Yeah, thanks a lot. I'd like to ask about the oncology data releases you have coming this year, the ones that might really shift things for the company. What are your expectations when it comes to the pivotal readouts for SV and mevro this year? And on a separate note, could you give us an update on how the restructuring of corporate strategy and business development operations is going? Thanks.
Many thanks, Dave. I'll handle the second part, and after that Chris will speak to SV and mevro; we made certain adjustments to our organizational structure, and those fit with our ongoing push to simplify. Over the coming couple of years — well, actually over the past two years — we've cut four members from my executive team. Business development was placed under Chris Boshoff, since the bulk of business development right now ties to the R&D pipeline and the choices around it. By doing that, we're seeing a meaningful reduction in whatever friction might have been there and a much smoother way of working; we also shifted commercial development — meaning all the commercial strategies that used to sit in that group — into the organization's global marketing. That likewise generates a considerable amount of synergies, because you have global and the new product together. Global market handles new products as well as our older ones; that now reports to Aamir. Alexandre picked up the responsibility of running the portfolio management team. He's the new chair. His focus is on prioritizing the pipeline. The strategy group was moved to my chief of staff, so it sits in the office of the CEO, which also lets me keep better oversight. Those are the changes that have taken place in our organization. We believe they line up with everything we had planned, namely simplifying our business. Chris.
Much appreciated. We'll kick things off with SV, which is a major program for us. Integrin beta-6 is a highly differentiated target — it's overexpressed in 90% of lung cancers, yet shows up only at minimal levels in normal lung tissue. The first-line data gave us encouragement — I mean the phase I results we shared — despite being just a single-arm experience, with a median overall survival of about 16.3 months. As a reminder, the second-line study is focused on non-squamous disease, which mirrors the signals we saw. It's a phase III trial against docetaxel. If the study turns out positive for overall survival, it has the statistical power, and it will also demonstrate clinical meaningfulness. Also worth mentioning, we currently have a phase III trial underway in the TPS high group, TPS above 50. At ASCO, we'll present data from the phase I experience — that's pembro versus pembro plus SV. Keep in mind that a year ago we showed results for that combination in PD-L1 high patients. It was a small number of patients, and all of them responded in that group, giving a 100% response rate in a limited population. Moving to mevrometostat, again a key differentiated, highly specific EZH2 agent. The first study we anticipate reading out is MEVPRO-1, which involves patients after abiraterone where there's considerable unmet need: enzalutamide versus enzalutamide plus EZH2 versus the physician's choice of enzalutamide or docetaxel. That readout is expected in the middle or latter half of this year, somewhere in the 14% to 15% range of our overall timeline. Thank you.
Thanks, Chris. Operator, let's take the next question.
Thanks a lot for taking these. I've got maybe just a couple. The first one is perhaps for Dave or for whoever else on the team wants to jump in. I realize that after the first quarter you normally don't move guidance up, but from a revenue standpoint this really does look like a strong way to begin the year. Could you speak in broad terms about how business trends are tracking relative to what you expected, and also about how you see the rest of the year unfolding? My second one relates to BD capacity. You brought up $7 billion. I suppose, now that there's clarity around VYNDAMAX, might the company consider bigger transactions if an attractive opportunity came along, or does the priority remain much more heavily on the internal pipeline, with perhaps smaller tuck-ins going forward? Thank you.
Chris, it's Dave. Thanks. On your first point, the company has gotten off to a genuinely strong start in Q1. Looking broadly, across every product and every dimension, we came in above expectations on both top line and bottom line, with truly robust cost control and cost management and very disciplined execution. Yes, that positions us quite well to deliver across the remainder of the year. As you're well aware, Chris, my approach is not to make adjustments in Q1. As you're also well aware, given the seasonality, our COVID franchise will always be weighted toward the back half; if anything, we've de-risked that delivery without moving guidance up. Were it not for that, we'd likely be raising guidance. How's that? Again, strong performance. Second, as I mentioned, we do have $7 billion in BD capacity. Clearly, this legal development actually leaves us more confident about our cash flow delivery across the coming several years, and we're always evaluating BD and figuring out what makes strategic sense on the BD front to serve the company's needs and deliver long-term value.
Thanks, Dave. Let's take the next one.
I appreciate you taking my question. Regarding COMIRNATY, I was hoping you could expand a bit on what vaccination rates you anticipate for this year across the U.S. as well as international markets. And then, turning back to the international side, could you elaborate a bit more on the contracts that already exist in Europe, and remind us about the phase payments tied to those existing agreements? Given that recent Belgian court ruling, when you consider those two things side by side, how should we view how ex-U.S. sales for that vaccine will develop?
All right, we'll begin with international, then Alexandre will take over, and after that Aamir will address vaccination rates in the U.S.
Yeah. No, that's a fair question, actually. To give you some background, the drop you're seeing in Q1 for COMIRNATY isn't tied to vaccination at all. What's really going on is a carryover effect from last year. We delivered the final contract components under our agreement with the U.K.; that contract is no longer ours in 2026, and that's the reason for the decrease. It isn't really a statement about vaccination rates. In fact, we looked at the vaccination figures across Europe for 2025, and they were largely steady compared with 2024. Naturally, there are variations. Take France, for example, where roughly 25% of adults are vaccinated; in Spain, it'll be somewhere near 35%. Those figures have held steady, and we're seeing a willingness from governments to keep investing and to raise awareness among their older and at-risk populations so they get vaccinated. During 2026, we'll be working with those governments throughout the European Union to keep carrying out our contract, just as we've done in prior years. Then, turning to the legal case and the court judgment dated April 1, 2026, that judgment is extremely clear, and we've begun working with the governments of Poland and Romania to carry it out, and we're talking over the best way forward for putting that judgment into effect.
Thank you, Alexandre. Aamir, what about the U.S.?
The way people get vaccinated across the U.S. clearly varies a lot depending on which group you look at. With COVID and COMIRNATY, the label ended up being narrowed, and because of that, we did observe the market contract somewhat. When it comes to RSV, we're clearly moving beyond our third season now, dealing with an adult population that's harder to reach, while the maternal side keeps expanding, plus there are population shifts affecting Prevnar among both children and adults. Those dynamics cause vaccination rates to rise and fall. What gives me real comfort and confidence is how we're performing in that marketplace. Looking at each of our MITs individually, we hold leading positions in the market. <<inaudible>> sits above 60%, COMIRNATY is above 60%, Prevnar for kids has reached 84% now, and Prevnar for adults, despite facing many months of competition from the market, is still holding its share firm at 70%. I feel really good about how we're carrying out our strategy in a market that's a bit unsettled.
Thank you for the confidence, Aamir. I share it with you. Next question, please.
Hello, everyone. Thank you for letting me ask. I value the remarks you shared regarding keeping the dividend intact. If I could, I'd like to look at this through a couple of separate lenses. To start, how probable is it that Pfizer would consider a transformative M&A deal in the near or medium term, which might wind up affecting the dividend, as has happened before historically? And second, Albert, how are you thinking personally, and how is the board thinking, about your time leading Pfizer and how that connects to dividend integrity going forward? Thanks so much.
Well, I, we never rule anything out, and we constantly evaluate every business, every potential business combination for M&A. If what you're really asking is whether, at this moment, we intend to pursue something extremely large, a major merger, then no. Our view is that right now, over the next 2 years, this is the moment to carry out AI transformation across these organizations. Doing that calls for avoiding the upheaval that a mega merger brings. I'd put it this way: we're open to anything, and we examine anything capable of creating shareholder value, but pursuing something of that kind isn't especially high on our list at present. As for the second question, how I view my tenure, I view it as ongoing. I've stated many times that I felt tremendous pride in what we managed to accomplish with COVID, yet once you've been spoiled by that sense of satisfaction, you want to repeat it. I intend to repeat it, and with any luck this time through cancer, obesity, and vaccines. Next question.
Thanks for taking my question. Albert, I want to revisit the guidance call from last December. At that time, you pointed out that LOEs would affect $17 billion in yearly revenue by 2030. Now that the tafamidis patent settlement pushes that date out to mid-2031, you've said the goal is high single-digit revenue growth over five years, beginning in 2029. Could you expand on that a bit more? Looking at the pipeline and the BD opportunities you just mentioned, please give us your latest thinking on how the gap gets bridged — what levers should we consider for driving that growth in light of the accumulating LOEs? On a similar note, within that high single-digit CAGR, how are you thinking about the base business assumptions — things like COVID and the current oncology products? Thank you.
Yeah, forecasting the base business is simpler, obviously, since it stays steady. It tracks the usual patterns we anticipate on a product-by-product basis. The LOEs are also straightforward to project, given that they're certain to happen. You're correct that at this point, with that product's LOE pushed back by 2.5 years — and it's worth $6 billion+ — this creates considerable opportunity, as you'd expect, for cash flows and EPS, and it shifts the growth trajectory. The reason we're talking about this right now is that there's so much uncertainty around what we've projected for our growth trajectory, which we've said kicks off in 2029. That works out to a high single-digit CAGR across five years. The way you get there is by combining what we have in the current portfolio, the erosion coming from LOEs, and pipeline products we've added that carry substantial risk adjustment. We aren't dealing with binary events here. As you're aware, there are many pipeline programs. A whole set of readouts is happening at this moment, and those will shape what revenue looks like in 2029. My confidence on this comes from the fact that once you have a big pool of pipeline assets with risk adjustment applied, the statistics tend to hold up. Some companies are going to make it and some aren't — that's just how it goes — and the risk adjustment accounts for that reality. When it comes to how this company grows starting in 2029, I have a lot of confidence, and I'm equally confident in how we're handling the LOEs, which, as you can see from where we stand today, is going quite smoothly. The LOEs already got underway this year. Another point I'd like to stress: our approach to LOEs has always centered on doing well with new and acquired products, since those were brought to market and brought in specifically to counterbalance the LOEs. This year they're up 22%. In a single quarter, they've already reached $3.1 billion. Suppose you take that figure and simply times it by four—not calling it official guidance, just as a rough way to size things—then what we're looking at is more than $12 billion for this year, and that number keeps climbing. As for the $17 billion in LOEs, once you account for VYNDA, the total comes closer to $14 billion to $15 billion instead of $17 billion. In my view, that's a solid picture. It's solid. Thanks. Let's take the next question.
Hello, everyone. I appreciate you letting me ask something. My focus is on how you're putting capital to work, particularly regarding buybacks. Dave, I'm aware this is a tool you've been keen to use; given that things are now clearer around VYNDAMAX and the CAGR beyond 2028, what additional signals would you need before possibly repurchasing stock, particularly given where prices sit today? Many thanks.
Yes, Evan, that's a solid inquiry. Our approach to allocating capital is something we constantly review, weighing the three avenues available to us. Right now, we're centered on funding our R&D platform alongside business development efforts to generate value over the long haul. The progress made in those court cases does leave us somewhat more assured about future cash generation. As you'll observe, when it comes to capital allocation, the share repurchase option will reenter the picture as a bigger priority moving forward. Good question, it's a topic we continually address, and our aim is always to serve the company and its shareholders best over the long term.
Thank you, Dave. Very clear. Next question, please.
Hello, Pfizer group. I appreciate your time in addressing this. I'd like to dig a bit deeper regarding sigvotatug vedotin and how it might be placed in the first-line setting, for all patients, when compared with the Symbiotic-Lung-01 trial that you've already launched involving the PD-1/VEGF. I also see that you have what looks like a phase I/II underway, testing the combination of these two assets. Could you assist in putting into context that upcoming phase III allcomers study you plan to begin this year for SV in first line, and how it might be situated against Symbiotic-Lung-01? Many thanks.
Okay, Chris.
Thanks so much for that question. Lung cancer clearly represents a major area where patients still lack options, and the fact that we now have several opportunities to make progress, thanks to a highly differentiated portfolio, makes us feel good about our ability to keep contributing meaningfully in this disease area, not only through targeted agents such as lorlatinib. Regarding SV, the results we've observed when combining pembrolizumab with PADCEV among patients whose PD-1 or PD-L1 levels are high have been quite encouraging — earlier, in a small patient group, every one of those with high PD-L1 responded to that regimen. The phase III trial now underway, comparing pembrolizumab against pembrolizumab for SV, is enrolling at a good pace in the first-line setting, and we have confidence in the results it will produce. A second-line trial is also running, testing against docetaxel. That one was prompted by prior findings, though from a single-arm study, showing a median overall survival of 16.3 months; results from this trial ought to arrive around the middle of the year. It pits docetaxel against SV in the second line, with statistical power designed, naturally, around overall survival. Should the outcome be favorable, then, as I mentioned before, it would carry real clinical significance. Additional trials are in the planning stages for a wider patient group, pairing treatment with chemo alongside pembrolizumab, and later in the year we'll disclose some early findings from that combination. Turning to 4404, at ASCO we'll present phase II results for 4404 used alone as monotherapy in first-line PD-L1 expressing non-small cell lung cancer. As you're aware, we recently presented findings at AACR, where we reproduced the preclinical and initial data that 3SBio had generated in China. Our confidence that this molecule stands apart is strong. Its binding to VEGF, as demonstrated at AACR, is superior, with greater affinity than what bevacizumab achieves, or what competing VEGF, PD-1 molecules achieve. We have faith in this molecule. More data will come later in the year as a broad program launches, covering combinations with chemo among others. One quick note: ASCO will also feature data on 4401 combined with chemo for first-line advanced recurrent endometrial cancer, another effort for which we intend to launch a phase III program.
Thank you, Chris. The next question. The last question.
Hello, and thank you for allowing me to pose a question. Which main offerings do you expect to fuel the pickup in your expansion during 2029 and afterward? When it comes to the chance in global obesity, I'm simply interested in what you gained from rolling out your GLP-1 in China. Thanks.
Yes. Alexandre, since obesity abroad — naturally, Lilly's figures have shown how substantial the overseas market is — let's have you go first once more, and also discuss the leading products that are going to propel your growth.
Right.
That would be 2029. Aamir, the main U.S. products that are going to fuel expansion come 2029.
That's a terrific question about how ecnoglutide is being introduced across China. Obviously, we're still extremely early in this process. The product only reached the market on Monday of last week, so merely 7 days have passed, and because of that I can't give you any read on ecnoglutide's penetration in China. What is truly striking is how common chronic weight problems are in China. Roughly 15% of the Chinese population deals with this, and with such a huge population in China, that makes it one of the larger markets for chronic weight management. That's the reason we chose back in February of this year to form this partnership with Sciwind Biosciences to commercialize ecnoglutide in China. From then on, we obtained approval and launched this asset. Ecnoglutide's profile looks very strong, and in fact a placebo-controlled trial demonstrated 15.1% weight loss at 48 weeks, alongside a 1.1 percent weight loss at 48 weeks observed in that same study, which puts it on par with the leading GLP-1 products; with this dual mechanism of action of GLP-1, we think we're bringing to market a highly effective asset that also offers a good tolerability profile. Of course, we'll leverage our very robust primary care skills and capabilities in China, which make Pfizer China one of the leaders in primary care. The combination of a highly attractive clinical profile together with our expertise in this space will, in our view, make us a leader in this category; we aren't coming very late to the market because, as you'll remember, Lilly actually launched their asset at the beginning of last year; it's not as if we're appearing many years after those assets came out. As I said, I'm quite optimistic, both because of this asset's profile and the capabilities we've built in China. On how this fits into the growth engine of the international segment, let me just step back for a moment. When you look at the quarter and the fact that our non-COVID primary care achieved double-digit growth, we delivered $2 billion this quarter. Keep in mind, we ended last year with double-digit growth in primary care. Turning to specialty care, it's roughly $1.5 billion this quarter. We're again delivering double-digit growth. That followed double-digit growth last year. There are assets across those different areas that will keep driving our growth. Coming back to primary care, our vaccines are growing very strongly. The reason we're growing so strongly on vaccines is that in both pneumococcal and RSV, we have a large population. As you know, in pneumococcal, this is a very large population, and two-thirds of our vaccine business comes from pediatric. Naturally, we have a large pediatric population to keep growing, so both in maternal immunization and in pneumococcal. The vaccines have potential to grow in pediatric and in adults. Of course, a big chunk of the growth we'll see as these decades wind down will come from the Metsera asset in chronic weight management, and there are two reasons for that. First, this is an area of unmet need, with a huge global epidemic, right? In some emerging markets, obesity prevalence is extremely high — in Saudi, in Brazil, in Mexico. Our presence in those markets, together with strong primary care, will allow us to really unlock that potential; on top of that, it's a cash market, which is another major plus in Europe, in Japan and other developed markets where we can launch those products right after approval, unlike the situation today across many of our categories, because payer reimbursement discussions take up a great deal of time. So as you can see, we have an inline asset that will keep fueling growth, and we're bringing in assets like the PADCEV that will go straight to market. Of course, the oncology asset is on the way, though reimbursement negotiation will take more time. In addition, we observed a 1.1 percent weight loss at 48 weeks.
Thank you, Alexandre. Aamir, now excite us for U.S.
Louise, to address that, a number of factors give us confidence we can drive growth in the U.S. in 2029. Take the first category: we have products already on the market that carry substantial upside. Consider PADCEV — essentially all of our recent growth has come from la/mUC. We're sitting at high 50% penetration there. There's considerable upside ahead in MIBC 303 and 304. Plenty of headroom exists for growth there. Then you look at a product such as NURTEC: we now have a strong tailwind behind us, and only 60% of people who write a triptan have yet to write an oral CGRP. There's a great deal of headroom for growth, and our execution against that is going really well. Next, consider some of our existing large franchises. We hold a lot of confidence in what will happen with VYNDA. With 2.5 years of additional exclusivity now, we have the chance to invest and keep growing diagnosis; we're doing an excellent job defending our existing patient base while also ensuring it remains the choice — the top choice — for new patient starts; we believe we have considerable momentum on franchises like that too. To add to what Alexandre was saying, thinking about new areas of growth, we've already discussed the oncology assets at length. Clearly, we're very excited about what we have to bring to the market in obesity. The assets speak for themselves, but what excites me particularly is that we possess unique capabilities as a company to win in this area — both in our ability to activate consumers and patients in very different ways, and in our legacy in this space, plus the fact that nearly 60% of physicians who are going to write these products, we already reach today through a combination of our field forces. Those combinations are just some examples of what gives us confidence to grow in 2029 and beyond.
Thanks, Aamir, and thanks to all of you for being here. The strong results we posted this quarter show what happens when we stay focused and execute with discipline. We're approaching things carefully so that our commercial portfolio delivers as much value as possible, and that's coming through in our financial numbers; over in R&D, we're moving ahead in a meaningful way, with a solid set of important milestones coming in 2026 that we expect will show even more clearly how strong and how broad our pipeline is. I'd like to thank my team here at Pfizer. In my view, no team Pfizer has ever had is better than this one. They're committed to our purpose, they keep delivering, and they fully take on our dedication to building long-term value for patients and for our shareholders. Thanks for being on the call today, and thanks for your interest in Pfizer; as we carry out our priorities across the year, we look forward to sharing more updates.
Thanks. That wraps up the meeting for today. We’re grateful for your time and for joining in. You’re welcome to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Pfizer Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Pfizer Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.